We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-6.38%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$952M
AUM Growth
+$36.2M
Cap. Flow
+$167M
Cap. Flow %
17.57%
Top 10 Hldgs %
50.62%
Holding
63
New
7
Increased
16
Reduced
13
Closed
4

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$67.2M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$61M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$50M
4
CBIO
Crescent Biopharma
CBIO
+$47.3M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$21M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$55.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$20.5M
3
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$19.5M
4
CYTK icon
Cytokinetics
CYTK
+$12.7M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$4.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHXM
51
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.77M 0.29%
62,500
– –
SURF
52
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$1.54M 0.16%
1,086,251
+65,017
+6% +$142K
MREO
53
Mereo BioPharma
MREO
$52.4M
$1.52M 0.16%
523,382
– –
RGLS
54
DELISTED
Regulus Therapeutics
RGLS
$1.47M 0.15%
203,570
– –
KDNY
55
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.07M 0.11%
+202,000
New +$1.34M
FRTX
56
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$947K 0.1%
5,069
-738
-13% -$169K
CFRX
57
DELISTED
ContraFect Corporation
CFRX
$680K 0.07%
2,374
– –
ALBO
58
DELISTED
Albireo Pharma Inc
ALBO
$580K 0.06%
29,000
-36,500
-56% -$945K
ELDN icon
59
Eledon Pharmaceuticals
ELDN
$261M
$522K 0.05%
46,049
– –
KPTI icon
60
Karyopharm Therapeutics
KPTI
$42.2M
– –
-23,684
Closed -$2.13M
CNCE
61
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-1,628,187
Closed -$19.5M
RLM
62
DELISTED
Realm Therapeutics plc American Depositary Shares
RLM
– –
-909,759
Closed -$2.57M
ARRY
63
DELISTED
Array Biopharma Inc
ARRY
– –
-1,193,224
Closed -$55.3M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2019 Portfolio in Review

As of Q3 2019, BVF Inc held 63 positions worth $952M, up 4% from $916M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

BVF Inc deployed $167M of net new capital in Q3 2019, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was SpringWorks Therapeutics: 2,844,145 shares worth $61.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $20.5M trimmed.

  • BVF Inc's largest Q3 2019 buy was SpringWorks Therapeutics: 2,844,145 shares worth $61.7M.
  • BVF Inc added most to Arqule Inc in Q3 2019, an estimated $12.5M increase.
  • BVF Inc's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $20.5M.
  • BVF Inc fully exited Array Biopharma Inc in Q3 2019, selling an estimated $55.3M.
  • BVF Inc's ten largest holdings make up 51% of its $952M portfolio in Q3 2019.
  • BVF Inc opened 7 new positions and closed 4 in Q3 2019.
  • BVF Inc's portfolio value rose 4% quarter-over-quarter to $952M.

Based on BVF Inc's 13F filing for Q3 2019, filed 14 Nov 2019.